Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2020

Jan 29, 2021

SELL
$4.87 - $17.29 $1.55 Million - $5.49 Million
-317,704 Closed
0 $0
Q3 2020

Oct 28, 2020

SELL
$15.08 - $27.04 $1.88 Million - $3.36 Million
-124,341 Reduced 28.13%
317,704 $5.22 Million
Q2 2020

Jul 28, 2020

BUY
$14.57 - $23.96 $70,227 - $115,487
4,820 Added 1.1%
442,045 $10.3 Million
Q1 2020

Apr 30, 2020

BUY
$10.27 - $21.23 $14,799 - $30,592
1,441 Added 0.33%
437,225 $6.48 Million
Q4 2019

Jan 29, 2020

SELL
$8.36 - $23.81 $8,610 - $24,524
-1,030 Reduced 0.24%
435,784 $8.92 Million
Q3 2019

Oct 31, 2019

SELL
$9.83 - $14.82 $251,716 - $379,495
-25,607 Reduced 5.54%
436,814 $4.29 Million
Q2 2019

Jul 31, 2019

SELL
$12.9 - $20.8 $76,858 - $123,926
-5,958 Reduced 1.27%
462,421 $6.24 Million
Q1 2019

May 01, 2019

BUY
$17.7 - $24.93 $1.4 Million - $1.97 Million
79,039 Added 20.3%
468,379 $9.22 Million
Q4 2018

Jan 30, 2019

SELL
$19.05 - $36.45 $133,159 - $254,785
-6,990 Reduced 1.76%
389,340 $8.81 Million
Q3 2018

Oct 31, 2018

BUY
$34.41 - $44.23 $5.61 Million - $7.21 Million
162,943 Added 69.82%
396,330 $14.7 Million
Q2 2018

Jul 31, 2018

BUY
$39.21 - $50.29 $4.14 Million - $5.31 Million
105,552 Added 82.57%
233,387 $9.15 Million
Q1 2018

Apr 26, 2018

SELL
$41.7 - $64.16 $2.66 Million - $4.1 Million
-63,830 Reduced 33.3%
127,835 $6.28 Million
Q4 2017

Feb 05, 2018

BUY
$28.58 - $49.91 $5.48 Million - $9.57 Million
191,665
191,665 $8.67 Million

Others Institutions Holding ASMB

# of Institutions
1
Shares Held
16.3K
Call Options Held
0
Put Options Held
0

About ASSEMBLY BIOSCIENCES, INC.


  • Ticker ASMB
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 48,436,900
  • Market Cap $723M
  • Description
  • Assembly Biosciences, Inc., a clinical-stage biotechnology company, discovers and develops therapeutic candidates for the treatment of hepatitis B virus (HBV) infection in the United States. The company's lead product candidate is Vebicorvir, which as completed Phase 2 clinical trials to treat patients with chronic HBV infection. It is also deve...
More about ASMB
Track This Portfolio

Track Emerald Advisers, LLC Portfolio

Follow Emerald Advisers, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Emerald Advisers, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Emerald Advisers, LLC with notifications on news.